A phase I, open-label, single-dose study to evaluate the effect of mild or moderate hepatic impairment on the pharmacokinetics of fenebrutinib
Autoimmune Disorder Multiple Sclerosis (MS) Metabolic Disorder Impaired hepatic function
For the latest version of this information please go to www.forpatients.roche.com